NCT04662528撤回3 期
A Phase 3, Placebo-Controlled, Randomized, Double-blind, Parallel-arm Trial to Assess the Safety and Efficacy of MAT9001 in Subjects With Severe Hypertriglyceridemia: The AMPLIFY Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 主要终点
- The percent change from baseline to end of study for MAT9001 versus Placebo
研究概览
简要总结
To determine the efficacy of MAT9001 compared to placebo in lowering fasting triglyceride levels in subjects with very high fasting triglyceride levels ≥ 500 and < 2000 mg/dL.
详细描述
This will be a 12-week, randomized, double blind, placebo-controlled safety and efficacy study in men and women ≥18 years of age with fasting triglycerides ≥500 mg/dL and <2000 mg/dL while following a Therapeutic Lifestyle changes (TLC) diet.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fasting triglycerides ≥500 mg/dL and <2000 mg/dL
- •Stable lipid-altering drug therapies permitted
- •Stable PCSK9 inhibitor use permitted
- •BMI ≥20.0 kg/m2
- •Willing to maintain a Therapeutic Life Change diet for the duration of the study
- •willing to maintain usual physical activity level for the duration of the study
- •willing to abstain from alcohol consumption for at least 24 hours prior to each study visit
- •agrees not to consume more than 2 meals/week containing fish or seafood
- •no plans to change smoking/vaping habits or other nicotine use during the study period
- •to be in generally good health on the basis of medical history, physical exam, electrocardiogram (ECG), and screening measurements
排除标准
- •Laboratory test result of clinical significance based on the judgment of the Principal Investigator
- •A clinically significant GI, endocrine, cardiovascular, renal, hepatic, pulmonary, pancreatic, neurologic, or biliary disorder
- •Known lipoprotein lipase impairment or deficiency or Apo C2 deficiency or familial dysbetalipoproteinemia
- •Acute or chronic pancreatitis
- •Symptomatic gallstone disease (unless previously treated with cholecystectomy).
- •Known nephrotic syndrome
- •Malabsorption syndrome and/or chronic diarrhea
- •Previous bariatric surgery or weight change >3 kg (6.6 lb) during the lead in period.
- •Diagnosed hereditary or acquired myopathy
- •Uncontrolled diabetes (HbA1c ≥9.5%)
- •Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg)
- •Uncontrolled hypothyroidism, thyroid stimulating hormone >5 mIU/L
- •History of cancer in the prior 2 years, except non melanoma skin cancer or carcinoma in situ of the cervix
- •History of human immunodeficiency virus, hepatitis B, or hepatitis C infection.
- •Active systemic infection.
- •History of paroxysmal atrial fibrillation, persistent atrial fibrillation, and/or history of ventricular tachycardic arrythmia (e.g., ventricular tachycardia/fibrillation)
- •History of a bleeding disorder
- •Use of omega 3 drugs /supplements /fortified foods
- •Use of bile acid sequestrants, fibrates, or niacin
- •Use of dietary supplement(s) that alters lipid metabolism
- •Use of weight management drug therapy
- •Cardiovascular disease event (myocardial infarction or other acute coronary syndrome, stroke, transient ischemic attack), revascularization procedure
- •Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period
- •Known allergy or sensitivity to any ingredients in the study products, including fish, seafood or omega 3 fatty acids
- •Been exposed to any investigational drug product within 30 days
- •Current or recent history or strong potential for illicit drug or excessive alcohol intake
- •A condition that would interfere with ability to provide informed consent or comply with the study protocol, or put the person at undue risk
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
MAT9001 (omega-3-pentaenoic acid)
Experimental
干预措施: MAT9001 (omega-3 pentaenoic acid) (Drug)
结局指标
主要结局
The percent change from baseline to end of study for MAT9001 versus Placebo
时间窗: 12 weeks
Difference between MAT9001 and placebo treatment groups in triglyceride lowering effect
次要结局
- The percent change from baseline to end of study for lipids and lipid biomarkers for MAT9001 versus Placebo(12 weeks)
研究者
相似试验
已完成
3 期
A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected PatientsHepatitis C, ChronicNCT01292239Janssen Pharmaceutical K.K.183
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic PatientsHealthy VolunteersDyslipidemiaNCT01487460Novartis Pharmaceuticals137
已完成
2 期
Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) HypertriglyceridemiaHypertriglyceridemiaNCT02250105Arisaph Pharmaceuticals Inc80
终止
3 期
Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01829477Takeda33
已完成
3 期
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous TherapyHepatitis CNCT01281839Janssen R&D Ireland394